In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant

Journal of Invasive Cardiology

Volumn 15, Issue 5, 2003, Pages 242-246

  Shammas, Nicolas W ^a   Lemke, Jon H ^b   Dippel, Eric J ^b   McKinney, Dawn E ^b   Takes, Vickie S ^b   Youngblut, Monica ^b   Harris, Melodee ^b   Harb, Catherine ^b   Kapalis, Matthew J ^b   Holden, Jane ^b  

^a Cardiovascular Medicine Davenport   (United States)

^b NONE

Author keywords

Major bleeding; Peripheral angioplasty; Unfractionated heparin; Vascular complications

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CIGARETTE SMOKING; CLAUDICATION; CLINICAL EXAMINATION; FEMALE; HOSPITAL PATIENT; HUMAN; LEG ULCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; REVASCULARIZATION; SURGICAL MORTALITY; THROMBUS; VASCULAR SURGERY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMORAL ARTERY; HEPARIN; HOSPITAL MORTALITY; HUMANS; ILIAC ARTERY; INTRAOPERATIVE COMPLICATIONS; IOWA; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; POPLITEAL ARTERY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0038613006     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Matsi PJ, Manninen HI. Complications of lower-limb percutaneous transluminal angioplasty: A prospective analysis of 410 procedures on 295 consecutive patients. Cardiovasc Intervent Radiol 1998;21:361-366.
2. Gutteridge W, Torrie EP, Galland RB. Cumulative risk of bypass, amputation or death following percutaneous transluminal angioplasty. Eur J Vasc Endovasc Surg 1997;14:134-139.
3. Axisa B, Fishwick G, Bolia A, et al. Complications following peripheral angioplasty. Ann R Coll Surg Engl 2002;84:39-42.
4. Morse MB, Jeans WD, Cole SE, et al. Complications in percutaneous transluminal angioplasty: Relationships with patient age. Br J Radiol 1991;64:5-9.
5. Hasson JE, Acher CW, Wojtowycz M, et al. Lower extremity percutaneous transluminal angioplasty: Multifactorial analysis of morbidity and mortality. Surgery 1990;108:748-752.
6. Boyer L, Therre T, Garcier JM, et al. Infrapopliteal percutaneous transluminal angioplasty for limb salvage. Acta Radiol 2000;41:73-77.
7. Greenfield AJ. Femoral, popliteal and tibial arteries: Percutaneous transluminal angioplasty. Am J Roentgenol 1980;135:927-935.
8. Narins CR, Hillegass WB Jr., Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
9. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal transluminal angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
10. Ogilby JD, Kopelman HA, Klein LW, Agarwal JB. Adequate heparinization during PTCA: Assessment using activated clotting times. Cathet Cardiovasc Diagn 1989;18:206-209.
11. Kleiman NS, Weitz JI. Putting heparin into perspective: Its history and the evolution of its use during percutaneous coronary interventions. J Invas Cardiol 2000;12(Suppl F):20F-26F.